Hr Positive Her2 Negative Breast Cancer Market Insights

DelveInsight’s ‘Hormone Receptor (HR) positive/ Human Epidermal Receptor 2 (HER2) negative Breast Cancer-Market Insights, Epidemiology and Market Forecast–2030’ report delivers an in-depth understanding of the HR-positive/ HER2-negative breast cancer, historical and forecasted epidemiology as well as the HR-positive/ HER2-negative breast cancer market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.


The HR-positive/ HER2-negative breast cancer market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM HR-positive/ HER2-negative breast cancer market size from 2017 to 2030. The Report also covers current HR-positive/ HER2-negative breast cancer treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.


Geography Covered

• The United States

• EU5 (Germany, France, Italy, Spain, and the United Kingdom)

• Japan


Study Period: 2017–2030


HR-positive/ HER2-negative breast cancer Disease Understanding and Treatment Algorithm

HR-positive/ HER2-negative breast cancer Overview

Breast cancer initiates when abnormal cancerous cells in the breast grow and multiply without stopping, creating a tumor. It usually form in the ducts or lobules of the breast. Cancer cells get many signals that drive their growth. These signals may take the form of hormones. Hormone receptors are proteins that receive hormone signals and initiate the cancer cells to growth.


If breast cancer cells get signals from the hormone estrogen that could promote tumor growth, it is known as estrogen receptor-positive (ER+) breast cancer. If cancerous cells receives signals from the hormone progesterone that could promote growth, it is known as progesterone receptor-positive (PR+) breast cancer. Breast cancer that is ER-positive or PR-positive falls under the category of hormone receptor-positive (HR+) breast cancer. Breast cancer cells may have one, both, or none of these receptors.


HR-positive/HER2-negative breast cancer is the most common form of breast cancer and also accounts for a higher percentage of all breast cancers. HR-positive cancer is usually treated with hormone therapies or a combination of hormone therapies with targeted therapy to help to stop tumor growth. Hormone therapies helps to prevent the cancer cells from receiving the estrogen for their growth. HR-positive tumors have a slightly lower chance of breast cancer coming back in the first few years after diagnosis than HR- tumors.


HR-positive/HER2-negative breast cancer Diagnosis

The diagnosis of breast cancer depends on the presentation of the lesion by mammographic screening, other radiological imaging (such as ultrasound) or by a physical presence. It is important to combine the radiologic assessment of the entire affected breast and the contralateral breast with the general health of the woman, for the examination of breast cancer diagnosis method used are Imaging test (Diagnostic mammography, Ultrasound and MRI), Biopsy, Genomic test to predict recurrence risk and Hormone Receptor Assays.

continued in the report…..


HR-positive/HER2-negative Breast Cancer Treatment

Breast Cancer is a highly heterogeneous disease and its successful management implies a multidisciplinary approach, which requires both local disease control and tailored systemic adjuvant therapy. Estrogen receptor (ER) expression is the main indicator of potential responses to hormonal therapy, and most of the human Breast Cancers are hormone-dependent and ER-Positive.


A number of classes of anti-estrogenic agents available for patients with early, advanced, or metastatic breast cancer which includes selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs), and a selective estrogen receptor degrader. However, the clinical development of combinations of antiestrogenic therapy with targeted agents that inhibit the phosphatidylinositol 3 kinase (PI3K)/akt murine thymoma viral oncogene (AKT)/mammalian target of rapamycin inhibitor (mTOR) signaling pathway or the cyclin-dependent kinase 4/6 (CDK4/6) pathway at the G1/S checkpoint of the cell cycle is currently a key focus of clinical research in patients with Hormone-Receptor Positive Breast Cancer who have demonstrated disease recurrence or progression.


The report covers the details of conventional and current medical therapies available in the HR-positive/HER2-negative breast cancer market for the treatment of the various types of breast cancer. It also provides the treatment guidelines and algorithms of the United States and Europe. 


The DelveInsight’s HR-positive/HER2-negative breast cancer market report gives a thorough understanding of HR-positive/HER2-negative breast cancer by including details such as disease definition, causes, risk factors, pathogenesis, and diagnosis. 


HR-positive/HER2-negative Breast cancer Epidemiology 

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Incidence of Breast Cancer, Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer, Diagnosed Incidence of HR+/HER2- post-menopausal metastatic Breast Cancer and Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer scenario of breast cancer in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.


Key Findings

This section provides glimpses of the HR-positive/HER2-negative breast cancer epidemiology in the 7MM.


• As per DelveInsight’s analysis, the total Incident Population of Breast Cancer in the 7MM was found to be 626,867 in 2017.

• The estimates show higher incidence of Breast Cancer in the United States with 266,120 cases in 2017.

• Amongs EU5, Germany show higher incidence of Breast Cancer followed by Italy and France, UK and Spain respectively


Country Wise- HR-positive/HER2-negative Breast Cancer Epidemiology

The epidemiology segment also provides the HR-positive/HER2-negative breast cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.


HR-positive/HER2-negative breast cancer Drug Chapters

The drug chapter segment of the HR-positive/HER2-negative breast cancer report encloses the detailed analysis of HR-positive/HER2-negative breast cancer marketed drugs, mid phase and late stage (phase III) pipeline drugs. It also helps to understand the HR-positive/HER2-negative breast cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.


HR-positive/HER2-negative breast cancer Marketed Drugs

Ibrance: Pfizer

Ibrance (Palbociclib) developed by Pfizer, is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. In February 2015, Pfizer received accelerated approval of ibrance from the US FDA. The drug is the first CDK 4/6 inhibitor approved in the US, in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease.

Products detail in the report…


Piqray: Novartis

Piqray (BYL719; ALPESLIB) is an orally bioavailable, alpha-specific PI3K inhibitor developed by Novartis. In breast cancer cell lines harboring PIK3CA mutations, BYL719 has been shown to potentially inhibit the PI3K pathway and have antiproliferative effects.

Products detail in the report…


Lynparza: AstraZeneca Pharmaceuticals

Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor including PARP1, PARP2, and PARP3. It is used in patients with deleterious or suspected deleterious gBRCAm, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting.

Products detail in the report…


Verzenio: Eli Lilly

Verzenio (Abemaciclib) is indicated for the treatment of women with hormone receptor (HR)-positive in combination with fulvestrant. It is also used for treatment of human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. And used as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Products detail in the report…


HR-positive/HER2-negative breast cancer Emerging Drugs

SHR6390: Jiangsu HengRui Medicine Co.

SHR6390 is cyclin-dependent kinases 4 and 6 (CDK4/6) developed by Jiangsu HengRui Medicine, are the key components of cell cycle progression and are dysregulated in cancers. Inhibition of CDK4/6 induces G1 phase cell cycle arrest, therefore retards tumor growth.

Products detail in the report…


Tesetaxel: Odonate Therapeutics

Tesetaxel (formerly known as DJ-927) is an investigational, orally administered chemotherapy agent developed by Odonate Therapeutics, belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. This is an orally administered chemotherapy.

Products detail in the report…


Elacestrant: Radius Pharmaceuticals

Elacestrant (RAD1901) is an investigational product candidate of Radius Pharmaceutical. The drug is a selective estrogen receptor degrader (SERD), for potential use in the treatment of hormone-receptor-positive breast cancer. It is currently being investigated in women with advanced estrogen receptor-positive (ER-positive) and human epidermal growth factor receptor 2-negative (HER2-negative) breast cancer, the most common subtype of the disease.

Products detail in the report…


Sacituzumab: Immunomedics

Sacituzumab govitecan (IMMU-132) is an advanced product candidate, which is a novel, first-in-class antibody-drug conjugate (ADC). Sacituzumab govitecan is an ADC that contains SN-38, the active metabolite of irinotecan, approved by many Health Authorities, including the US Food and Drug Administration (FDA) as a chemotherapeutic for patients with cancer.

Products detail in the report…


HR-positive/HER2-negative breast cancer Market Outlook

The stage (extent) of the breast cancer is an important factor in making decisions about treatment. Most women with breast cancer in stages I, II, or III are treated with surgery, often followed by radiation therapy. Many women also get some kind of drug therapy. Most women with breast cancer in stages I to III will get some kind of drug therapy as part of their treatment. This may include chemotherapy, hormone therapy (tamoxifen, an aromatase inhibitor, or one followed by the other), HER2 targeted drugs, such as trastuzumab (Herceptin) and pertuzumab (Perjeta), and some combination of these. The types of drugs that might work best depend on the tumor’s hormone receptor status, HER2 status, and other factors.


The HR-positive/HER2-negative breast cancer market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted HR-positive/HER2-negative breast cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.


This segment gives a thorough detail of HR-positive/HER2-negative breast cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.


According to DelveInsight, HR-positive/HER2-negative breast cancer 7MM is expected to change in the study period 2017–2030.


Key Findings


• The market size of HR-positive/HER2-negative postmenopausal breast cancer in the 7MM was found to be USD 5,237.2 million in 2017.

• Among the 7MM countries, the United States had the highest market size of HR-positive/HER2-negative breast cancer in 2017, which accounts for approximately 80.51% of the total market.


The United States Market Outlook

This section provides the total HR-positive/HER2-negative breast cancer market size and market size by therapies in the United States.


EU-5 Market Outlook

The total HR-positive/HER2-negative breast cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.


Japan Market Outlook

The total HR-positive/HER2-negative breast cancer market size and market size by therapies in Japan are provided.


HR-positive/HER2-negative breast cancer Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the HR-positive/HER2-negative breast cancer market or expected to get launched in the market during the study period 2017–2030. The analysis covers HR-positive/HER2-negative breast cancer market uptake by drugs; patient uptake by therapies; and sales of each drug.  


This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


HR-positive/HER2-negative Breast Cancer Development Activities

The report provides insights into different therapeutic candidates in phase II, and phase III stage. It also analyzes key players involved in developing targeted therapeutics.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for HR-positive/HER2-negative breast cancer emerging therapies.


Reimbursement Scenario in HR-positive/HER2-negative Breast Cancer

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In the report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.


Competitive Intelligence Analysis

We perform competitive and market Intelligence analysis of the HR-positive/HER2-negative breast cancer market by using various competitive intelligence tools that include–SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability. 


Scope of the Report

• The report covers the descriptive overview of HR-positive/HER2-negative breast cancer, explaining its causes, signs and symptoms, pathogenesis and currently available therapies.

• Comprehensive insight has been provided into the HR-positive/HER2-negative breast cancer epidemiology and treatment.

• Additionally, an all-inclusive account of both the current and emerging therapies for HR-positive/HER2-negative breast cancer are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.

• A detailed review of HR-positive/HER2-negative breast cancer market; historical and forecasted is included in the report, covering the 7MM drug outreach.

• The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM HR-positive/HER2-negative breast cancer market.


Report Highlights

• In the coming years, HR-positive/HER2-negative breast cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.

• The companies and academics are working to assess challenges and seek opportunities that could influence HR-positive/HER2-negative breast cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.

• Major players are involved in developing therapies for HR-positive/HER2-negative breast cancer. Launch of emerging therapies will significantly impact the HR-positive/HER2-negative breast cancer market.

• Our in-depth analysis of the pipeline assets across different stages of development (phase III and phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.


HR-positive/HER2-negative breast cancer Report Insights

• Patient Population

• Therapeutic Approaches

• HR-positive/HER2-negative breast cancer Pipeline Analysis

• HR-positive/HER2-negative breast cancer Market Size and Trends

• Market Opportunities

• Impact of upcoming Therapies


HR-positive/HER2-negative breast cancer Report Key Strengths

• Eleven Years Forecast

• 7MM Coverage

• HR-positive/HER2-negative breast cancer Epidemiology Segmentation

• Key Cross Competition

• Highly Analyzed Market

• Drugs Uptake


HR-positive/HER2-negative breast cancer Report Assessment

• Current Treatment Practices

• Unmet Needs

• Pipeline Product Profiles

• Market Attractiveness

• Market Drivers and Barriers


Key Questions

Market Insights:

• What was the HR-positive/HER2-negative breast cancer market share (%) distribution in 2017 and how it would look like in 2030?

• What would be the HR-positive/HER2-negative breast cancer total market size as well as market size by therapies across the 7MM during the forecast period (2020–2030)?

• What are the key findings pertaining to the market across the 7MM and which country will have the largest HR-positive/HER2-negative breast cancer market size during the forecast period (2020–2030)?

• At what CAGR, the HR-positive/HER2-negative breast cancer market is expected to grow at the 7MM level during the forecast period (2020–2030)?

• What would be the HR-positive/HER2-negative breast cancer market outlook across the 7MM during the forecast period (2020–2030)?

• What would be the HR-positive/HER2-negative breast cancer market growth till 2030 and what will be the resultant market size in the year 2030?

• How would the market drivers, barriers and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

• What is the disease risk, burden and unmet needs of HR-positive/HER2-negative breast cancer`?

• What is the historical HR-positive/HER2-negative breast cancer patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?

• What would be the forecasted patient pool of HR-positive/HER2-negative breast cancer at the 7MM level?

• What will be the growth opportunities across the 7MM with respect to the patient population pertaining to HR-positive/HER2-negative breast cancer?

• Out of the above-mentioned countries, which country would have the highest incident population of HR-positive/HER2-negative breast cancer during the forecast period (2020–2030)?

• At what CAGR the population is expected to grow across the 7MM during the forecast period (2020–2030)?


Current Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the treatment of HR-positive/HER2-negative breast cancer along with the approved therapy?

• What are the current treatment guidelines for the treatment of HR-positive/HER2-negative breast cancer in the US and Europe?

• What are the HR-positive/HER2-negative breast cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?

• How many companies are developing therapies for the treatment of HR-positive/HER2-negative breast cancer?

• How many therapies are developed by each company for the treatment of HR-positive/HER2-negative breast cancer?

• How many emerging therapies are in the mid-stage and late stage of development for the treatment of HR-positive/HER2-negative breast cancer?

• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the HR-positive/HER2-negative breast cancer therapies?

• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?

• What are the clinical studies going on for HR-positive/HER2-negative breast cancer and their status?

• What are the key designations that have been granted for the emerging therapies for HR-positive/HER2-negative breast cancer?

• What are the 7MM historical and forecasted market of HR-positive/HER2-negative breast cancer?


Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the HR-positive/HER2-negative breast cancer.
  • To understand the future market competition in the HR-positive/HER2-negative breast cancer market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for HR-positive/HER2-negative breast cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for HR-positive/HER2-negative breast cancer market.
  • To understand the future market competition in the HR-positive/HER2-negative breast cancer market.


What will be the total incident population of breast cancer in the 7MM by 2030?

The total incident population of breast cancer in the 7MM is expected to rise to 698,212 by 2030 during the study period [2017–2030].


What was the market size of postmenopausal breast cancer in the 7MM in 2017?

The market size of postmenopausal breast cancer in the 7MM was found to be USD 5,237.24 Million in 2017.


What are the HR-positive/HER2-negative Breast Cancer market drivers?

Rich Emerging Pipeline, Novel Chemotherapeutic Approaches and New Endocrine Targeted Therapies to Overcome Resistance are the HR-positive/HER2-negative Breast Cancer market drivers.


What are the HR-positive/HER2-negative Breast Cancer market barriers?

Economic Burden, Predictive Biomarkers and Currently Available Therapies are the HR-positive/HER2-negative Breast Cancer market barriers.


Which companies are developing drugs for HR-positive/HER2-negative Breast Cancer?

Jiangsu HengRui Medicine Co., Odonate Therapeutics, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merrimack Pharmaceuticals, GlaxoSmithKline, Takeda Pharmaceuticals, Eagle Pharmaceuticals are developing drugs for HR-positive/HER2-negative Breast Cancer.


1 Key Insights

2 SWOT Analysis for Breast Cancer

3 Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer Market Overview at a Glance

3.1 Total Market Share (%) Distribution of HR-positive/HER2-negative in 2017

3.2 Total Market Share (%) Distribution of HR-positive/HER2-negative in 2030

4 Disease Background and Overview: Hormone Receptor (HR)-positive/ Human Epidermal Receptor 2 (HER2)-negative Breast Cancer

4.1 Introduction

4.2 Types of Breast Cancer

4.2.1 Subtypes of Breast Cancer

4.2.2 Molecular Subtypes of Breast Cancer

4.3 Estrogen Receptor (ER)-Positive Breast Cancer

4.3.1 Estrogen Receptor

4.3.2 Estrogen Receptor 1 Mutations

4.3.3 PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) Gene

4.3.4 GATA 3

4.4 Metabolic Pathway of Estrogen Receptor (ER)-Positive Breast Cancer

4.4.1 Role of Estrogen Receptor Alpha (ERα) in Regulating Breast Cancer Metabolism

4.5 Symptoms of HR-Positive Breast Cancer

4.6 Risk Factors of Estrogen Receptor (ER)-Positive Breast Cancer

4.6.1 Lifestyle-related Breast Cancer Risk Factors

4.6.2 Changes in Other Genes

4.6.3 Having a Family History of Breast Cancer

4.6.4 Having Dense Breast Tissue

4.7 Diagnosis of Estrogen Receptor (ER)-Positive Breast Cancer

4.7.1 Imaging Tests

4.7.2 Biopsy

4.7.3 Genomic Tests to Predict Recurrence Risk

4.7.4 Additional tests

4.8 Diagnostic Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer

4.8.1 American Society of Clinical Oncology (ASCO)

5 Recognized Establishments

6 Epidemiology and Patient Population

6.1 Key Findings

6.2 Population and Forecast Parameters

6.3 Total Incidence of Breast Cancer in the 7MM

6.4 Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM

6.5 Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM

6.6 Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM

7 Country-Wise Epidemiology of Hormone Receptor (HR) Positive Breast Cancer

7.1 United States

7.1.1 Assumptions and Rationale

7.1.2 Total Incidence of Breast Cancer in the United States

7.1.3 Incidence of Breast Cancer Cases by Menopausal Status in the United States

7.1.4 Stage-Specific Incidence of Breast Cancer in Post Menopausal Women in the United States

7.1.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States

7.1.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in the United States

7.1.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in the United States

7.2 EU5 Countries

7.3 Germany

7.3.1 Assumptions and Rationale

7.3.2. Total Incidence of Breast Cancer in Germany

7.3.3. Incidence of Breast Cancer Cases by Menopausal Status in Germany

7.3.4. Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany

7.3.5. Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany

7.3.6. Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Germany

7.3.7. Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Germany

7.4 France

7.4.1 Assumptions and Rationale

7.4.2 Total Incidence of Breast Cancer in France

7.4.3 Incidence of Breast Cancer Cases by Menopausal Status in France

7.4.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France

7.4.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France

7.4.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in France

7.4.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in France

7.5 Italy

7.5.1 Assumptions and Rationale

7.5.2 Total Incidence of Breast Cancer in Italy

7.5.3 Incidence of Breast Cancer Cases by Menopausal Status in Italy

7.5.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy

7.5.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy

7.5.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Italy

7.5.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Italy

7.6 Spain

7.6.1 Assumptions and Rationale

7.6.2 Total Incidence of Breast Cancer in Spain

7.6.3 Incidence of Breast Cancer by Menopausal Status in Spain

7.6.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain

7.6.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain

7.6.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause Cases by Molecular Subtype in Spain

7.6.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause Cases by Molecular Subtype in Spain

7.7 The United Kingdom

7.7.1 Assumptions and Rationale

7.7.2 Total Incidence of Breast Cancer in the United Kingdom

7.7.3 Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom

7.7.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United Kingdom (2017–2030)

7.7.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United Kingdom

7.7.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in the United Kingdom

7.7.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in the United Kingdom

7.8 Japan

7.8.1 Assumptions and Rationale

7.8.2 Total Incidence of Breast Cancer in Japan

7.8.3 Incidence of Breast Cancer Cases by Menopausal Status in Japan

7.8.4 Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Japan (2017–2030)

7.8.5 Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the Japan

7.8.6 Diagnosed Incidence of Early Stage Breast Cancer in Post-menopause by Molecular Subtype in Japan

7.8.7 Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Post-menopause by Molecular Subtype in Japan

8 Treatment of Estrogen-Receptor (ER)-Positive Breast Cancer

8.1.1 Endocrine Therapy

8.1.2 Aromatase inhibitors (AIs)

8.1.3 Endocrine Therapy (ET) Options to Manage Resistance

8.1.4 Targeted CDK4/6 Inhibitors

8.1.5 mTOR Inhibitors

8.1.6 Akt Inhibitors

8.2 Treatment Algorithm of Estrogen Receptor (ER)-Positive Breast Cancer

8.3 Treatment Guidelines for Estrogen-Receptor (ER) Positive Breast Cancer

8.3.1 American Society of Clinical Oncology (ASCO) Clinical Practice Guideline: Adjuvant Endocrine Therapy for Women with Hormone-receptor-positive Breast Cancer

8.3.2 Italian Association of Medical Oncology (AIOM): Adjuvant Endocrine Therapy in Premenopausal Patients with Hormone-receptor-positive Early Breast Cancer

8.3.3 The Japanese Breast Cancer Society: Clinical Practice Guideline for systemic treatment of breast cancer

9 Marketed Products

9.1 Ibrance (Palbociclib): Pfizer

9.1.1 Product Description

9.1.2 Regulatory Milestones

9.1.3 Other Developmental Activities

9.1.4 Current Pipeline Activity

9.1.5 Safety and efficacy

9.1.6 Product Profile

9.2 Piqray (Alpelisib; BYL719): Novartis

9.2.1 Product Description

9.2.2 Regulatory Milestones

9.2.3 Other Developmental Activities:

9.2.4 Clinical Development

9.2.5 Safety and Efficacy

9.2.6 Product Profile

9.3 Lynparza (olaparib): AstraZeneca Pharmaceuticals

9.3.1 Product Description

9.3.2 Regulatory Milestones

9.3.3 Other Developmental Activities

9.3.4 Clinical Development

9.3.5 Safety and efficacy

9.3.6 Product Profile

9.4 Verzenio (Abemaciclib): Eli Lilly

9.4.1 Product Description

9.4.2 Regulatory Milestones

9.4.3 Other Developmental Activities

9.4.4 Clinical Development

9.4.5 Safety and efficacy

9.4.6 Product Profile

9.5 Kisqali (Ribociclib; LEE011): Novartis Pharmaceuticals

9.5.1 Product Description

9.5.2 Regulatory Milestones

9.5.3 Other Developmental Activities

9.5.4 Clinical Development

9.5.5 Safety and efficacy

9.5.6 Product Profile

9.6 Afinitor (Everolimus): Novartis

9.6.1 Product Description

9.6.2 Regulatory Milestones

9.6.3 Other Developmental Activities

9.6.4 Clinical Development

9.6.5 Safety and efficacy

9.6.6 Product Profile

9.7 Faslodex (Fulvestrant) Injection: AstraZeneca

9.7.1 Product Description

9.7.2 Regulatory Milestones

9.7.3 Other Developmental Activities

9.7.4 Clinical Development

9.7.5 Safety and efficacy

9.7.6 Product Profile

9.8 Arimidex (Anastrozole): AstraZeneca

9.8.1 Product Description

9.8.2 Regulatory Milestones

9.8.3 Other Developmental Activities

9.8.4 Clinical Development

9.8.5 Safety and efficacy

9.8.6 Product Profile

9.9 Aromasin (Exemestane): Pharmacia and Upjohn Company

9.9.1 Product Description

9.9.2 Regulatory Milestones

9.9.3 Other Developmental Activities

9.9.4 Clinical Development

9.9.5 Safety and Efficacy

9.9.6 Product Profile

9.1 Femara (Letrozole): Novartis Pharmaceuticals

9.10.1 Product Description

9.10.2 Regulatory Milestones

9.10.3 Other Developmental Activities

9.10.4 Clinical Development

9.10.5 Safety and efficacy

9.10.6 Product Profile

10 Unmet Needs

11 Emerging Drugs

11.1 Key Cross Competition

11.2 SHR6390: Jiangsu HengRui Medicine Co.

11.2.1 Product Description

11.2.2 Clinical Development

11.2.3 Safety and Efficacy

11.2.4 Product Profile

11.3 Tesetaxel: Odonate Therapeutics

11.3.1 Product Description

11.3.2 Other Development Activities

11.3.3 Clinical Development

11.3.4 Safety and Efficacy

11.3.5 Product Profile

11.4 Elacestrant (RAD1901): Radius Pharmaceuticals

11.4.1 Product Description

11.4.2 Other Development Activities

11.4.3 Clinical Development

11.4.4 Safety and Efficacy

11.4.5 Product Profile

11.5 Sacituzumab Govitecan (IMMU-132): Immunomedics

11.5.1 Product Description

11.5.2 Other Development Activities

11.5.3 Clinical Development

11.5.4 Product Profile

11.6 Ipatasertib (RG7440): Roche

11.6.1 Product Description

11.6.2 Clinical Development

11.6.3 Product Profile

11.7 Venclexta: Roche

11.7.1 Product Description

11.7.2 Other Development Activities

11.7.3 Clinical Development

11.7.4 Safety and Efficacy

11.7.5 Product Profile

11.8 Entinostat: Syndax Pharmaceuticals

11.8.1 Product Description

11.8.2 Other Developmental Activities

11.8.3 Clinical Development

11.8.4 Safety and Efficacy

11.8.5 Product Profile

11.9 Pembrolizumab (MK-3475): Merck Sharp and Dohme

11.9.1 Product Description

11.9.2 Other development Activities

11.9.3 Clinical Development

11.9.4 Product Profile

11.10.1 Product Description

11.10.2 Other development Activities

11.10.3 Clinical Development

11.10.4 Product Profile

11.11 MM-121: Merrimack Pharmaceuticals

11.11.1 Product Description

11.11.2 Other Development Activities

11.11.3 Clinical Development

11.11.4 Safety and Efficacy

11.11.5 Product Profile

11.12 GSK525762 (Molibresib): GlaxoSmithKline

11.12.1 Product Description

11.12.2 Other Development Activities

11.12.3 Clinical Development

11.12.4 Safety and Efficacy

11.12.5 Product Profile

11.13 Sapanisertib (TAK-228): Takeda Pharmaceuticals

11.13.1 Product Description

11.13.2 Other Development Activities

11.13.3 Clinical Development

11.13.4 Safety and Efficacy

11.13.5 Product Profile

11.14 Radium-223 dichloride: Bayer

11.14.1 Product Description

11.14.2 Other Development Activities

11.14.3 Clinical Development

11.14.4 Product Profile

11.15 EGL-5385-C-1701(fulvestrant): Eagle Pharmaceuticals

11.15.1 Product Description

11.15.2 Other Development Activities

11.15.3 Clinical Development

11.15.4 Product Profile

12 HR+/HER2- Post Menopause Breast Cancer: The 7 Major Market Analysis

12.1 Key Findings

12.1.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM

12.1.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM

12.1.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the 7MM

12.1.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM

12.1.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM

13 The United States Market Analysis

13.1 The United States Market Outlook

13.2 United States Market Size

13.2.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States

13.2.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United States

13.2.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United States

13.2.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States

13.2.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States

14 EU-5 Market Analysis

14.1 EU-5 Market Outlook

14.2 Germany Market Size

14.2.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany

14.2.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Germany

14.2.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Germany

14.2.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany

14.2.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany

14.3 France Market Size

14.3.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France

14.3.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in France

14.3.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in France

14.3.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France

14.3.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France

14.4 Italy Market Size

14.4.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy

14.4.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Italy

14.4.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Italy

14.4.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy

14.4.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy

14.5 Spain Market Size

14.5.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain

14.5.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Spain

14.5.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Spain

14.5.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain

14.5.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain

14.6 The United Kingdom Market Size

14.6.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom

14.6.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom

14.6.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in the United Kingdom

14.6.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom

14.6.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United Kingdom

15 Japan Market Outlook

15.1 Japan Market Size

15.1.1 Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan

15.1.2 Market Size of Current Therapies for HR-positive/HER2-negative Breast Cancer in Japan

15.1.3 Market Size of Emerging Therapies for HR-positive/HER2-negative Breast Cancer in Japan

15.1.4 First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan

15.1.5 Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan

16 Access and Reimbursement Overview of Breast Cancer

17 Case Reports

17.1 Case Study in Breast Cancer: Primary Treatment of HR-positive, HER2-negative Advanced Breast Cancer

17.2 Case Studies in the Management of Metastatic Breast Cancer with Eribulin

18 Market Drivers

19 Market Barriers

20 Appendix

20.1 Report Methodology

21 DelveInsight Capabilities

22 Disclaimer

23 About DelveInsight

Table 1: Total Incidence of Breast Cancer in the 7MM (2017–2030)

Table 2: Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2030)

Table 3: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM

Table 4: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM

Table 5: Total Incidence of Breast Cancer in the United States (2017–2030)

Table 6: Incidence of Breast Cancer by Menopausal Status in the United States (2017–2030)

Table 7: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)

Table 8: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)

Table 9: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)

Table 10: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)

Table 11: Incidence of Breast Cancer in Germany (2017–2030)

Table 12: Incidence of Breast Cancer by Menopausal Status in Germany (2017–2030)

Table 13: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)

Table 14: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)

Table 15: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)

Table 16: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)

Table 17: Total Incidence of Breast Cancer in France (2017–2030)

Table 18: Incidence of Breast Cancer by Menopausal Status in France (2017–2030)

Table 19: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)

Table 20: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)

Table 21: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)

Table 22: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)

Table 23: Total Incidence of Breast Cancer in Italy (2017–2030)

Table 24: Incidence of Breast Cancer by Menopausal Status in Italy (2017–2030)

Table 25: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)

Table 26: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)

Table 27: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)

Table 28: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)

Table 29: Total Incidence of Breast Cancer in Spain (2017–2030)

Table 30: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2030)

Table 31: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)

Table 32: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)

Table 33: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Spain (2017–2030)

Table 34: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Spain (2017–2030)

Table 35: Total Incidence of Breast Cancer in the United Kingdom (2017–2030)

Table 36: Incidence of Breast Cancer by Menopausal Status in the United Kingdom (2017–2030)

Table 37: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)

Table 38: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)

Table 39: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)

Table 40: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)

Table 41: Total Incidence of Breast Cancer in Japan (2017–2030)

Table 42: Incidence of Breast Cancer by Menopausal Status in Japan (2017–2030)

Table 43: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Japan (2017–2030)

Table 44: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the Japan (2017–2030)

Table 45: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)

Table 46: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)

Table 47: Classification of Aromatase Inhibitors

Table 48: Summary of All Recommendations (Original Recommendations and Focused Update Recommendations)

Table 49: Ibrance, Clinical Trial Description, 2020

Table 50: Piqray, Clinical Trial Description, 2019

Table 51: Olaparib, Clinical Trial Description, 2020

Table 52: Verzenio, Clinical Trial Description, 2020

Table 53: KISQALI, Clinical Trial Description, 2020

Table 54: Faslodex, Clinical Trial Description, 2020

Table 55: Arimidex, Clinical Trial Description, 2020

Table 56: SHR6390, Clinical Trial Description, 2020

Table 57:, Tesetaxel, Clinical Trial Description, 2020

Table 58: Elacestrant (RAD1901), Clinical Trial Description, 2020

Table 59: Sacituzumab govitecan, Clinical Trial Description, 2020

Table 60: Ipatasertib, Clinical Trial Description, 2020

Table 61: Venetoclax, Clinical Trial Description, 2020

Table 62: Entinostat, Clinical Trial Description, 2020

Table 63: Pembrolizumab, Clinical Trial Description, 2020

Table 64: Eribulin Mesylate, Clinical Trial Description, 2020

Table 65: Seribantumab, Clinical Trial Description, 2020

Table 66: GSK525762 (Molibresib), Clinical Trial Description, 2020

Table 67: TAK-228 (INK128, MLN0128), Clinical Trial Description, 2020

Table 68: Radium 223 dichloride (BAY88-8223), Clinical Trial Description, 2020

Table 69: EGL-5385-C-1701(fulvestrant): Clinical Trial Description, 2020

Table 70: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM, USD Millions (2017–2030)

Table 71: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 72:7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 73: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)

Table 74: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)

Table 75: Novel drugs recently approved for treating HR-positive/ HER2-negative Breast Cancer

Table 76: Expected Launch Date of Emerging Drugs in the United States

Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2030)

Table 78: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 79:United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)

Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)

Table 82: Expected Launch Date of Emerging Drugs in EU-5 Countries

Table 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany, USD Millions (2017–2030)

Table 78: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 79: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)

Table 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)

Table 82: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France, USD Millions (2017–2030)

Table 83: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 84: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 85: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)

Table 86: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)

Table 87: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy, USD Millions (2017–2030)

Table 88: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 89: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 90: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)

Table 91: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)

Table 92: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain, USD Millions (2017–2030)

Table 93: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 94: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 95: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)

Table 96: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)

Table 97: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom, USD Millions (2017–2030)

Table 98: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 99: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 100: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)

Table 101: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)

Table 102: Expected Launch Date of Emerging Drugs in Japan

Table 103: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan, USD Millions (2017–2030)

Table 104: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Table 105: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Table 106: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)

Table 107: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)

Figure 1: SWOT analysis for Breast Cancer

Figure 2: Types of Receptor on Breast Cancer

Figure 3: Molecular Subtypes of Breast Cancer

Figure 4: Molecular Subtypes of Breast Cancer

Figure 5: Working of Estrogen Receptor

Figure 6: Schematic Structure of the Estrogen Receptor (ER) Depicting Six Domains.

Figure 7: ER pathway and mechanisms of resistance. Estrogen-bound estrogen receptor (ER), in association with a variety of coactivators and co-repressors, exerts its classical genomic action as a transcription factor through the estrogen response element (ERE) of target genes.

Figure 8: Metabolism of Estrogen Receptor-Positive Breast Cancer

Figure 9: Symptoms of HR-Positive Breast Cancer.

Figure 10: Lifestyle-related Breast Cancer Risk Factors

Figure 11: Diagnosis of ER-Positive Breast Cancer

Figure 12: Assays for Measuring Estrogen and Progesterone Receptor

Figure 13: Essential Elements Required for Accurate Testing of ERa And PGr Status In Breast Cancer by Immunohistochemistry.

Figure 14: Total Incidence of Breast Cancer in the 7MM (2017–2030)

Figure 15:Diagnosed Incidence of HR+/HER2- post-menopausal early stage Breast Cancer in the 7MM (2017–2030)

Figure 16: Diagnosed Incidence of HR+/HER2- post-menopausal advanced and metastatic stage Breast Cancer in the 7MM

Figure 17: Total Diagnosed Incidence of HR+/HER2- post-menopausal Breast Cancer in the 7MM

Figure 18: Total Incidence of Breast Cancer in the United States (2017–2030)

Figure 19: Incidence of Breast Cancer Cases by Menopausal Status in the United States (2017–2030)

Figure 20: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)

Figure 21: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the United States (2017–2030)

Figure 22: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)

Figure 23: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United States (2017–2030)

Figure 24: Total Incidence of Breast Cancer in Germany (2017–2030)

Figure 25: Incidence of Breast Cancer Cases by Menopausal Status in Germany (2017–2030)

Figure 26: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)

Figure 27: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Germany (2017–2030)

Figure 28: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)

Figure 29: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype Cases in Germany (2017–2030)

Figure 30: Total Incidence of Breast Cancer in France (2017–2030)

Figure 31: Incidence of Breast Cancer Cases by Menopausal Status in France (2017–2030)

Figure 32: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)

Figure 33: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in France (2017–2030)

Figure 34: Diagnosed Incidence of early Stage Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)

Figure 35: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in France (2017–2030)

Figure 36: Total Incidence of Breast Cancer in Italy (2017–2030)

Figure 37: Incidence of Breast Cancer Cases by Menopausal Status in Italy (2017–2030)

Figure 38: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)

Figure 39: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Italy (2017–2030)

Figure 40: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)

Figure 41: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Italy (2017–2030)

Figure 42: Total Incidence of Breast Cancer in Spain (2017–2030)

Figure 43: Incidence of Breast Cancer by Menopausal Status in Spain (2017–2030)

Figure 44: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)

Figure 45: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in Spain (2017–2030)

Figure 46: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause Cases by Molecular Subtype in Spain (2017–2030)

Figure 47: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause Cases by Molecular Subtype in Spain (2017–2030)

Figure 48: Total Incidence of Breast Cancer in the United Kingdom (2017–2030)

Figure 49: Incidence of Breast Cancer Cases by Menopausal Status in the United Kingdom (2017–2030)

Figure 50: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)

Figure 51: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the UK (2017–2030)

Figure 52: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)

Figure 53: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in the United Kingdom (2017–2030)

Figure 54: Total Incidence of Breast Cancer in Japan (2017–2030)

Figure 55: Incidence of Breast Cancer Cases by Menopausal Status in Japan (2017–2030)

Figure 56: Stage Specific Incidence of Breast Cancer in Post Menopausal Women in Japan2017–2030)

Figure 57: Stage Specific Diagnosed Incidence of Breast Cancer in Post Menopausal Women in the Japan (2017–2030)

Figure 58: Diagnosed Incidence of Early Stage Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)

Figure 59: Diagnosed Incidence of Locally Advanced and Metastatic Breast Cancer in Postmenopause by Molecular Subtype in Japan (2017–2030)

Figure 60: Endocrine Therapy for Breast Cancer

Figure 61: Mechanisms of action of different hormone therapy agents like SERMs, SERDs, AIs, and LHRH analogs. Hormones have shown in this picture: Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).

Figure 62: Picture showing a few molecules and molecular pathways that are involved in the induction of hormone therapy resistance in Estrogen Receptor-Positive Breast Cancer Cells.

Figure 63: Treatment Algorithm for Patients With Hormone Receptor–Positive, HER2 (Human Epidermal Growth Factor Receptor 2)–Negative Metastatic Breast Cancer.

Figure 64: Treatment Algorithm for Endocrine Therapy for Hormone-receptor-positive Metastatic Breast Cancer

Figure 65: Unmet Needs

Figure 66: Key Cross Competition

Figure 67: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the 7MM, USD Millions (2017–2030)

Figure 68: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 69: 7MM Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 70: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)

Figure 71: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The 7MM, in USD Million (2017–2030)

Figure 72: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United States, USD Millions (2017–2030)

Figure 73: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 74: United States Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 75: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)

Figure 76: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: The United States, in USD Million (2017–2030)

Figure 77: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Germany, USD Millions (2017–2030)

Figure 78: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 79: Germany Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 80: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)

Figure 81: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Germany, in USD Million (2017–2030)

Figure 82: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in France, USD Millions (2017–2030)

Figure 83: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 84: France Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 85: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)

Figure 86: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: France, in USD Million (2017–2030)

Figure 87: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Italy, USD Millions (2017–2030)

Figure 88: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 89: Italy Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 90: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)

Figure 91: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Italy, in USD Million (2017–2030)

Figure 92: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Spain, USD Millions (2017–2030)

Figure 93: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 94: Spain Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 95: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)

Figure 96: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Spain, in USD Million (2017–2030)

Figure 97: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in the United Kingdom, USD Millions (2017–2030)

Figure 98: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 99: United Kingdom Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 100: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)

Figure 101: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: United Kingdom, in USD Million (2017–2030)

Figure 102: Total Market Size of HR+/HER2-Post-menopausal Breast Cancer in Japan, USD Millions (2017–2030)

Figure 103: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Current Therapies, in USD Million (2017–2030)

Figure 104: Japan Market Size of HR+/HER2-Post-menopausal Breast Cancer by Emerging Therapies, in USD Million (2017–2030)

Figure 105: First Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)

Figure 106: Second Line HR+/HER2- post-menopausal advanced & metastatic Breast Cancer Market Size: Japan, in USD Million (2017–2030)

Figure 107: Market Drivers

Figure 108: Market Barriers

  • Tags:
  • HER2-/HR+ Breast Cancer market
  • HER2-/HR+ Breast Cancer market re...
  • HER2-/HR+ Breast Cancer market i...
  • HER2-/HR+ Breast Cancer market tr...
  • HER2-/HR+ Breast Cancer market fo...
  • HER2-/HR+ Breast Cancer market sh...
  • HER2-/HR+ Breast Cancer pipeline...
  • HER2-/HR+ Breast Cancer treatmen...
  • HER2-/HR+ Breast Cancer drugs
  • HER2-/HR+ Breast Cancer sales for...
  • HER2-/HR+ Breast Cancer market si...
  • HER2-/HR+ Breast Cancer disease
  • HER2-/HR+ Breast Cancer epidemiol...
  • HER2-/HR+ Breast Cancer

Forward to Friend

Need A Quote